Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO

• Published in: PloS one Vol. 14; no. 6; p. e0215739
• Main Authors: Ramanan, A V, Hampson, L V, Lythgoe, H, Jones, A P, Hardwick, B, Hind, H, Jacobs, B, Vasileiou, D, Wadsworth, I, Ambrose, N, Davidson, J, Ferguson, P J, Herlin, T, Kavirayani, A, Killeen, O G, Compeyrot-Lacassagne, S, Laxer, R M, Roderick, M, Swart, J F, Hedrich, C M, Beresford, M W
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 05.06.2019; Public Library of Science (PLoS)
• Subjects: Adalimumab; Adalimumab - therapeutic use; Adolescents; Analysis; Anti-inflammatory agents; Arthritis; Bayes Theorem; Bayesian analysis; Biocompatibility; Biology and Life Sciences; Biomedical materials; Bisphosphonates; Care and treatment; Children; Children & youth; Childrens health; Chronic pain; Clinical trials; Consensus; Cytokines; Disease; Drugs; Female; Fractures; Glucocorticoids; Hospitals; Humans; Immunotherapy; Inflammation; Male; Medical research; Medicine; Medicine and Health Sciences; Methods; Monoclonal antibodies; Nonsteroidal anti-inflammatory drugs; Osteomyelitis; Osteomyelitis - complications; Osteomyelitis - drug therapy; Pain; Pain Management; Pamidronate; Pamidronate - therapeutic use; Pamidronic acid; Patients; Pediatrics; People and Places; Phosphonates; Randomization; Randomized Controlled Trials as Topic; Rare diseases; Research and Analysis Methods; Research Design; Rheumatology; Teenagers; TNF inhibitors; Tumor necrosis factor; Womens health; United Kingdom; United Kingdom > UK; Denmark; Aarhus Denmark
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0215739

Chronic nonbacterial osteomyelitis (CNO) is a rare autoinflammatory bone disorder primarily affecting children and adolescents. It can lead to chronic pain, bony deformities and fractures. The pathophysiology of CNO is incompletely understood. Scientific evidence suggests dysregulated expression of pro- and anti-inflammatory cytokines to be centrally involved. Currently, treatment is largely based on retrospective observational studies and expert opinion. Treatment usually includes nonsteroidal anti-inflammatory drugs and/or glucocorticoids, followed by a range of drugs in unresponsive cases. While randomised clinical trials are lacking, retrospective and prospective non-controlled studies suggest effectiveness of TNF inhibitors and bisphosphonates. The objective of the Bayesian consensus meeting was to quantify prior expert opinion. Twelve international CNO experts were randomly chosen to be invited to a Bayesian prior elicitation meeting. Results showed that a typical new patient treated with pamidronate would have an 84% chance of improvement in their pain score relative to baseline at 26 weeks and an 83% chance on adalimumab. Experts thought there was a 50% chance that a new typical patient would record a pain score of 28mm (pamidronate) to 30mm (adalimumab) or better at 26 weeks. There was a modest trend in prior opinion to indicate an advantage of pamidronate vs adalimumab, with a 68% prior chance that pamidronate is superior to adalimumab by some margin. However, it is clear that there is considerable uncertainty about the precise relative merits of the two treatments. The rarity of CNO leads to challenges in conducting randomised controlled trials with sufficient power to provide a definitive outcome. We address this using a Bayesian design, and here describe the process and outcome of the elicitation exercise to establish expert prior opinion. This opinion will be tested in the planned prospective CNO study. The process for establishing expert consensus opinion in CNO will be helpful for developing studies in other rare paediatric diseases.